LearnGlossaryMarketStocksSuperinvestorsSign in

SIBN

SI-BONE, Inc.

Healthcare · $832M market cap

Verdict

We can't put a fair value on SIBN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth1.3% a year✗
Sales growth15.2% a year✓
Free cash flow growth—?
Return on invested capital-16.7%✗

Follow SIBN

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds SIBN. In Q2 2026, 1 added. Who we track

First Eagle Investment Management

First Eagle Investment Management · as of Q2 2026

$12.5M

768,941 shares

Moves in Q2 2026

Added: First Eagle Investment Management

Insider activity

Since Sep 1, 2026: no open-market purchases, 2 sales worth $378K and 2 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

DUNN JEFFREY W

director · 2026-09-01

Sold

$26K

DUNN JEFFREY W

director · 2026-09-01

Sold

$352K

Other filings

DUNN JEFFREY W

director · 2026-09-01

Option exercise

$6K

DUNN JEFFREY W

director · 2026-09-01

Option exercise

$87K

About SI-BONE, Inc.

SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works